Optinose Stock Today
| OPTN Stock | USD 5.36 0.01 0.19% |
PerformanceVery Weak
| Odds Of DistressVery High
|
OptiNose is selling at 5.36 as of the 16th of March 2025; that is 0.19 percent decrease since the beginning of the trading day. The stock's open price was 5.37. OptiNose has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of October 2017 | Category Healthcare | Classification Health Care |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. The company has 10.06 M outstanding shares of which 241.03 K shares are now shorted by private and institutional investors with about 14.38 trading days to cover. More on OptiNose
Moving together with OptiNose Stock
Moving against OptiNose Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
OptiNose Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, Director | Peter Miller | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOptiNose can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand OptiNose's financial leverage. It provides some insight into what part of OptiNose's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
OptiNose (OPTN) is traded on NASDAQ Exchange in USA. It is located in 1020 Stony Hill Road, Yardley, PA, United States, 19067 and employs 132 people. OptiNose is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 53.9 M. OptiNose conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 10.06 M outstanding shares of which 241.03 K shares are now shorted by private and institutional investors with about 14.38 trading days to cover.
OptiNose currently holds about 78.26 M in cash with (20.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.94.
Check OptiNose Probability Of Bankruptcy
Ownership AllocationThe market capitalization of OptiNose is $53.9 Million. The majority of OptiNose outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in OptiNose to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in OptiNose. Please pay attention to any change in the institutional holdings of OptiNose as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check OptiNose Ownership Details
OptiNose Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 86.2 K | |
| Rice Hall James & Associates, Llc | 2024-12-31 | 74.5 K | |
| Gmt Capital Corp | 2024-12-31 | 74 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 68.5 K | |
| Prescott Group Capital Management Llc | 2024-12-31 | 60.1 K | |
| Blackrock Inc | 2024-12-31 | 55.9 K | |
| Prudential Investment Management Inc | 2024-09-30 | 49.2 K | |
| Easterly Investment Partners. | 2024-12-31 | 46.7 K | |
| Jane Street Group Llc | 2024-12-31 | 28.6 K | |
| Fmr Inc | 2024-12-31 | 1.1 M | |
| Nantahala Capital Management, Llc | 2024-12-31 | 986 K |
OptiNose Historical Income Statement
OptiNose Stock Against Markets
OptiNose Corporate Management
| Anthony Krick | Vice Officer | Profile | |
| Michele MBA | VP CFO | Profile | |
| Terence Kohler | Chief Officer | Profile | |
| Paul Spence | Chief Officer | Profile | |
| John Messina | Sr Affairs | Profile | |
| Karen Brophy | Chief Resources | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.35) | Revenue Per Share | Quarterly Revenue Growth 0.031 | Return On Assets | Return On Equity |
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.